Advertisement

Ovarian Cancer pp 255-260 | Cite as

Regulatory T Cells: A New Frontier in Cancer Immunotherapy

  • Brian G. Barnett
  • Jens Rüter
  • Ilona Kryczek
  • Michael J. Brumlik
  • Pui Joan Cheng
  • Benjamin J. Daniel
  • George Coukos
  • Weiping Zou
  • Tyler J. Curiel
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 622)

Tumor-specific immune-mediate cancer therapy was documented in a mouse model about one and half century ago (1). Nonetheless, the success of immune-based cancer treatments in humans has remained quite modest despite advances in our understanding and technology. The current paradigm driving most immune strategies is that tumors express tumor-associated antigens (TAA), thereby making them the objects of immune attack. These TAA should then be captured by professional antigen-presenting cells, particularly dendritic cells, which in turn prime naïve T cells to become TAA-specific effector cells through T cell cosignaling molecules and other mediators. This paradigm predicts that the solution to improving the efficacy of tumor immunotherapy is to augment TAA expression, boost cosignaling, or increase the number of effector T cells or professional antigen-presenting cells. Experience shows, however, that with a few limited exceptions, such strategies do not yield durable clinical successes.

Keywords

Ovarian Cancer Ovarian Carcinoma Epithelial Ovarian Carcinoma Single Intravenous Dose Epithelial Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer 2008

Authors and Affiliations

  • Brian G. Barnett
  • Jens Rüter
  • Ilona Kryczek
  • Michael J. Brumlik
  • Pui Joan Cheng
  • Benjamin J. Daniel
  • George Coukos
    • 1
  • Weiping Zou
  • Tyler J. Curiel
    • 2
  1. 1.Center for Research on the Early Detection and Cure of Ovarian CancerUniversity of PennsylvaniaPhiladelphia
  2. 2.Department of Internal MedicineTulane University School of MedicineNew Orleans

Personalised recommendations